FDA Approves Fylnetra (pegfilgrastim-pbbk), Biosimilar to Neulasta (pegfilgrastim), for Treating Neutropenia
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a…